SINO BIOPHARM won the "Company of the Year" award at the 2025 BayHelix Awards

According to reporters at the BioCentury-BayHelix 12th China Healthcare Summit, China National Pharmaceutical Group (SINO BIOPHARM) has won the 2025 BayHelix Awards "Company of the Year" award, thanks to its groundbreaking acquisition of Lixin Pharmaceutical for approximately $1 billion in July this year. BioCentury stated that this year, SINO BIOPHARM completed a nearly $1 billion merger with Lixin Pharmaceutical, a rare instance of a domestic pharmaceutical company acquiring a local innovator in China's increasingly mature biotechnology ecosystem. This transaction enabled SINO BIOPHARM to gain eight clinical projects at once